WallStSmart

Danaher Corporation (DHR)vsSotera Health Co (SHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Danaher Corporation generates 2011% more annual revenue ($24.57B vs $1.16B). DHR leads profitability with a 14.7% profit margin vs 6.7%. DHR appears more attractively valued with a PEG of 1.23. SHC earns a higher WallStSmart Score of 62/100 (C+).

DHR

Buy

60

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 7.3Quality: 6.3
Piotroski: 4/9Altman Z: 2.36

SHC

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.5Value: 4.7Quality: 5.8
Piotroski: 6/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DHRSignificantly Overvalued (-38.6%)

Margin of Safety

-38.6%

Fair Value

$135.07

Current Price

$187.15

$52.08 premium

UndervaluedFair: $135.07Overvalued
SHCSignificantly Overvalued (-37.4%)

Margin of Safety

-37.4%

Fair Value

$12.64

Current Price

$13.70

$1.06 premium

UndervaluedFair: $12.64Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DHR4 strengths · Avg: 8.3/10
Market CapQuality
$134.43B9/10

Large-cap with strong market position

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.2%8/10

Strong operational efficiency at 22.2%

Free Cash FlowQuality
$1.75B8/10

Generating 1.7B in free cash flow

SHC1 strengths · Avg: 10.0/10
Operating MarginProfitability
35.7%10/10

Strong operational efficiency at 35.7%

Areas to Watch

DHR3 concerns · Avg: 3.7/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.6%4/10

4.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

SHC4 concerns · Avg: 3.8/10
PEG RatioValuation
1.684/10

Expensive relative to growth rate

Revenue GrowthGrowth
4.6%4/10

4.6% revenue growth

EPS GrowthGrowth
1.8%4/10

1.8% earnings growth

Profit MarginProfitability
6.7%3/10

6.7% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : DHR

The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.23 suggests the stock is reasonably priced for its growth.

Bull Case : SHC

The strongest argument for SHC centers on Operating Margin.

Bear Case : DHR

The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : SHC

The primary concerns for SHC are PEG Ratio, Revenue Growth, EPS Growth. A P/E of 51.2x leaves little room for execution misses. Debt-to-equity of 4.14 is elevated, increasing financial risk.

Key Dynamics to Monitor

SHC carries more volatility with a beta of 1.88 — expect wider price swings.

SHC is growing revenue faster at 4.6% — sustainability is the question.

DHR generates stronger free cash flow (1.7B), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SHC scores higher overall (62/100 vs 60/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Danaher Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.

Sotera Health Co

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.

Want to dig deeper into these stocks?